Ainos : PROMISSORY NOTE EXTENSION AGREEMENT - Form 8-K
August 22, 2023 at 07:26 pm IST
Share
PROMISSORY NOTE EXTENSION AGREEMENT
This Promissory Note Agreement (the "Agreement") is entered into this 17th day of August, 2023 (the "Effective Date") by and between Ainos, Inc., a Texas corporation (the "Maker"), and i2China Management Group, LLC, a Delaware limited liability company, or its successors or assigns (the "Holder").
RECITALS
A.
The Parties entered into Non-Convertible Promissory Note dated January 1, 2020 for the Principal Amount of $84,000 with 1.85% per annum interest on unpaid principal and accrued interest, and a maturity date of January 1, 2021 (the "Note").
B.
As of the Effective Date of this Agreement, the unpaid principal under the Note amounts to $42,000 and interest has accrued on all unpaid balances.
AGREEMENT
NOW, THEREFORE, the Parties agree as follows:
1.
The maturity date of the Note is hereby extended to September 1, 2024.
2.
Maker reserves its right to prepay all or part of the principal and/or interest pursuant to the Note, and accrued interest shall be equitably adjusted on the outstanding principal of any such payment.
3.
All other terms and conditions of the Note shall continue in full force and effect.
IN WITNESS WHEREOF, the undersigned Maker and Holder have duly executed this Extension Agreement.
Ainos Inc. published this content on 22 August 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 August 2023 13:55:18 UTC.
Ainos, Inc. is a diversified healthcare company, which is focused on the development of point-of-care testing (POCT), low-dose VELDONA interferon therapeutics and synthetic Ribonucleic Acid (RNA)-driven preventative medicine. The Company's products include VELDONA clinical-stage human therapeutics, VELDONA Pet cytoprotein health supplements, and telehealth-friendly POCTs powered by its AI Nose technology platform. VELDONA Pet is formulated to address a variety of health issues in dogs and cats, including skin, gum, emotion, discomfort caused by allergies, eye, and weight-related issues. Its pipeline of products, which are under development, includes VELDONA human drugs, VOC POCT-Ainos Flora, VOC platform-NISD co-development, VOC POCT-Ainos Pen, VOC POCT-CHS430 and Synthetic RNA. VELDONA human drugs are the high-priority programs include oral warts for human immunodeficiency virus seropositive patients, common cold, influenza, Sjogrens syndrome and treatment for mild COVID-19 symptoms.